Literature DB >> 2472228

Blood levels and serum protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.

B Schechter1, M A Rosing, M Wilchek, R Arnon.   

Abstract

Plasma levels and serum protein binding of cis-diamminedichloroplatinum(II) (cis-DDP) or cis-diamminediaquoplatinum(II) (cis-aq) complexed to carboxymethyl-dextran (CM-dex) with a molecular weight of 10,000 (T-10), 40,000 (T-40), and 250,000 (T-250) were investigated in BALB/c mice. Levels of active drug in the circulation after the i.v. or i.p. administration of the free or complexed drugs, as well as the loss of drug activity due to serum protein binding following incubation with mouse serum, were monitored by an antitumor in vitro assay using a drug-sensitive tumor cell line. Following i.v. injection of the complexes, active platinum(II) was maintained in the circulation at higher levels and for a longer period, whereas the free drug disappeared rapidly. The rate of disappearance of the complexed drug from the circulation was markedly influenced by the molecular size of the carrier CM-dex, since the retained amount of drug was considerably higher with the T-40 and T-250 complexes than with the T-10 complex. An i.p. injection resulted in a rapid and transient appearance of low levels of the free drugs in the blood, whereas in the case of the complexes, transport to the circulation was slower and their maintenance in the blood system was markedly higher. Serum protein binding was much slower with CM-dex-complexed drugs (regardless of the molecular size of the CM-dex carrier) than with the free drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472228     DOI: 10.1007/bf00300236

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; A A Hart; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1984-03

3.  The clinical setting and pharmacology of intraperitoneal chemotherapy: an overview.

Authors:  C E Myers
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

4.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

5.  Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).

Authors:  R J Belt; K J Himmelstein; T F Patton; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

6.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.

Authors:  S B Howell; C E Pfeifle; W E Wung; R A Olshen
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

8.  Effect of mannitol and plasma on the cytotoxicity of cisplatin.

Authors:  E E Holdener; C H Park; R J Belt; R L Stephens; B Hoogstraten
Journal:  Eur J Cancer Clin Oncol       Date:  1983-04

9.  Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma.

Authors:  B Schechter; M Wilchek; R Arnon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

10.  Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.

Authors:  K Takahashi; T Seki; K Nishikawa; S Minamide; M Iwabuchi; M Ono; S Nagamine; H Horinishi
Journal:  Jpn J Cancer Res       Date:  1985-01
View more
  1 in total

1.  Mitochondria-acting carrier-free nanoplatform self-assembled by α-tocopheryl succinate carrying cisplatin for combinational tumor therapy.

Authors:  Heng Mei; Jing Li; Shengsheng Cai; Xuequan Zhang; Wenqiang Shi; Hai Zhu; Jun Cao; Bin He
Journal:  Regen Biomater       Date:  2021-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.